Last reviewed · How we verify

Clustoid® Max Forte — Competitive Intelligence Brief

Clustoid® Max Forte (Clustoid® Max Forte) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

phase 2 Immunology Biologic Live · refreshed every 30 min

Target snapshot

Clustoid® Max Forte (Clustoid® Max Forte) — Inmunotek S.L.. Clustoid® Max Forte is an immunotherapeutic agent designed to modulate immune responses, likely through allergen immunotherapy or immune tolerance induction.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Clustoid® Max Forte TARGET Clustoid® Max Forte Inmunotek S.L. phase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clustoid® Max Forte — Competitive Intelligence Brief. https://druglandscape.com/ci/clustoid-max-forte. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: